what is a fair price at this stage of the game, page-5

i agree patty. But markets look at future earnings, i think the share price could be fair value of some 400 million before cvac being approved for commercialisation and even before phase 111 results. DNDN obviously is ahead off prr in terms of trials, but they have a market cap of approx 3 billion. i see a premium for prr still to come based on possible commercialisation of a product similar to one that is receiving massive attention in america, and based on this, there could be excitement still with prr. GOODLUCK :)